Amid the evolving landscape of the pharmaceutical sector, Supernus Pharmaceuticals (SUPN) has delivered impressive growth, with its stock price rising 31% over the past year. However, despite the recent rally, Supernus still trades 20% below its 2018 highs, leading some investors to question whether the stock can sustain its momentum or if it is time...
Why Today’s Inflation Data Tells an Incomplete Story
Markets opened cautiously this morning as traders prepared for the November Consumer Price Index release at 8:30 AM Eastern Time. A senior financial analyst at Logirium examines why this particular inflation report carries more uncertainty than usual and what investors should focus on beyond the headline numbers. The Bureau of Labor Statistics will publish November...
The $10 Billion Deal That Broke Tech’s Back
Technology shares suffered their worst session in months on Wednesday as investors reassessed the massive capital requirements behind artificial intelligence infrastructure buildouts. The Nasdaq 100 plunged 1.9% while the S&P 500 dropped 1.2%, with both indexes breaching technical support levels that had held for weeks. Logirium‘s lead financial analyst examines the sharp technology sector retreat...
Digital Gold Loses Its Shine
Bitcoin extended its decline Tuesday, falling to $85,266 and marking its fourth consecutive losing session. The world’s largest cryptocurrency has now dropped 30% from its October all-time high near $126,000. Market psychology has shifted dramatically as the digital asset struggles to maintain key technical levels. A senior broker at Logirium breaks down the cryptocurrency market’s...
Fed Cuts Again But Signals Caution Ahead
The Federal Reserve delivered another quarter-point rate cut on Wednesday, lowering the benchmark range to 3.5-3.75%. The move fulfilled market expectations but carried warning flags about future policy direction. Three committee members dissented, marking the first three-way split since September 2019. A financial expert at Logirium examines the central bank’s third consecutive rate reduction and...
Black Gold’s Brutal Year-End Collapse
West Texas Intermediate crude tumbled 2.73% on Tuesday, settling at $55.27 per barrel and marking its weakest close since the pandemic lows of February 2021. The global Brent benchmark declined 2.71% to $58.92, with both oil grades hovering around levels not seen in four years, even as geopolitical tensions flare across multiple regions. A lead...
Silicon Valley’s Favorite Stock Hits the Skids
Nvidia shares plunged 3.8% Wednesday to their lowest level since September, extending a brutal stretch for the semiconductor giant. The stock has now declined in eight consecutive trading sessions. This represents the longest losing streak for the company in over two years. Logirium‘s senior financial advisor explores Nvidia’s slide to September lows as the AI...
Memory Maker Defies Market Gloom
Micron Technology delivered quarterly results on Wednesday evening that defied the pessimism gripping technology markets. The memory chip manufacturer forecast second-quarter adjusted profit of $8.42 per share, nearly double consensus expectations. Shares surged 14% in after-hours trading as investors digested the surprise. A financial analyst at Logirium takes a closer look at Micron’s blockbuster forecast...
The Ghost of Christmas Rally Past
The S&P 500 recorded its fourth consecutive losing session on Wednesday, falling 1.16% to 6,721.43. The traditional “Santa Claus rally” appears missing in action despite historical patterns suggesting strength during late December. Year-end optimism has given way to persistent selling pressure. Logirium‘s junior financial expert explores the conspicuous absence of year-end strength as markets struggle...
Medical Giant’s Market Debut Dwarfs 2025 Listings
Medline shares surged 41% in their Wednesday market debut, closing at $41 after pricing at $29 per share. The medical supplies distributor’s performance in 2025 was the strongest year for initial public offerings since 2021. The company now commands a market capitalization exceeding $54 billion. Logirium‘s junior broker analyzes the blockbuster first-day performance of Medline’s...